Chronic Obstructive Pulmonary Disease Exhibits Emerging Pipeline with 60+ Drug Candidates

The study analyzed that the chronic obstructive pulmonary disease pipeline comprises 65 drug candidates, of which eight drug candidates are in Phase III stage of development, 24 drug candidates are in Phase II stage, nine drug candidates are in Phase I, 22 drug candidates are in Pre-Clinical stage and two drug candidates are in Discovery stage. Chronic obstructive pulmonary disease is a broad term used for progression of various other diseases that affect the lungs such as, emphysema, chronic bronchitis. In this condition, lung cells lose their elasticity and get enlarged, which leads to reduction in the amount of gas exchange in the lungs. Sometimes, it progresses to form cancer, stroke and coronary artery disease.

Explore Report at: https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis

As per the findings of the research, around 40.0% of the drug candidates of chronic obstructive pulmonary disease pipeline are being developed to be administered by inhalation route, 12.0% are being developed to be administered by oral route, 5.0% are being developed to be administered by subcutaneous route, 3.0% are being developed to be administered by intravenous route, 3.0% are being developed to be administered by another route and 37.0% are being developed to be administered by other routes that are undisclosed.

Many companies are involved in the development of drugs for the chronic obstructive pulmonary disease therapeutics pipeline, with their products in different phases. Chiesi Farmaceutici S.p.A., GlaxoSmithKline plc and AstraZeneca plc have their drug candidates in the Phase III stage of development. Adamis Pharmaceuticals Corporation has two drug candidates in Phase II stage of development. Novartis AG also has two drug candidates in Phase II stage of development. Glenmark Pharmaceuticals Ltd. has two drug candidates in Pre-Clinical stage of development.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis/report-sample

The research also found that various companies have collaborated for the development of chronic obstructive pulmonary disease therapeutics pipeline. In March 2017, Kyowa Hakko Kirin Co., Ltd. entered into an agreement with AstraZeneca plc for the exclusive rights of benralizumab for the treatment of severe asthma and chronic obstructive pulmonary disease in Asia. In June 2013, AstraZeneca plc acquired Pearl Therapeutics, Inc., which was involved in the development of inhaled small-molecule therapeutics for respiratory disease.

Some of the key players developing drugs for the treatment of chronic obstructive pulmonary disease include AstraZeneca plc, GlaxoSmithKline plc, Adamis Pharmaceuticals Corporation, Chiesi Farmaceutici S.p.A., Cytokinetics, Inc., Novartis AG and Theravance Biopharma R & D, Inc.